| Adalimumab Pharmacology |
| Adalimumab |
| About Adalimumab |
| Immunosuppressants, Human Monoclonal Antibody, Anti Rheumatic drug |
| Mechanism of Action of Adalimumab |
| Adalimumab is a recombinant DNA-derived human Ig G1 monoclonal antibody. It binds to human tumor necrosis factor alpha (TNF-?), thus interfering with cytokine-driven inflammatory processes |
| Pharmacokinets of Adalimumab |
| Absorption: Absorbed after SC administration Distribution: Widely distributed to the body Excretion: Excreted mainly through urine |
| Onset of Action for Adalimumab |
| N/A |
| Duration of Action for Adalimumab |
| N/A |
| Half Life of Adalimumab |
| 10 to 20 days |
| Side Effects of Adalimumab |
| 1.Hyperlipidaemia 2.Hypercholesterolaemia 3.Hypokalaemia 4.Hyperuricaemia 5.Headache 6.Drowsiness 7.Dizziness 8.Agitation 9.Tremor 10.Urinary frequency |
| Contra-indications of Adalimumab |
| Hypersensitivity |
| Special Precautions while taking Adalimumab |
| 1.Hepatic impairment 2.Renal impairment 3.Heart failure |
| Pregnancy Related Information |
| Contraindicated |
| Old Age Related Information |
| Use with caution |
| Breast Feeding Related Information |
| Contraindicated |
| Children Related Information |
| Use with caution |
| Indications for Adalimumab |
| 1.Rheumatoid arthritis 2.Ankylosing spondylitis 3.Crohn?s disease 4.Psoriatic arthritis 5.Ulcerative colitis |
| Interactions for Adalimumab |
| Avoid concomitant use of adalimumab with anakinra and live vaccines |
| Typical Dosage for Adalimumab |
| Dose for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic disease: 40 mg every other wk Dose for Crohn?s disease: 40 mg every other wk. For severe active disease: Initially, 160 mg given as 4 divided doses over 1-2 days, then 80 mg 2 wk after the initial dose. Maintenance: 40 mg every other wk; may increase to 40 mg wkly if needed |
| Schedule of Adalimumab |
| N/A |
| Storage Requirements for Adalimumab |
| Store between 2 to 8 degree celcius.Keep out of the reach of children |
| Effects of Missed Dosage of Adalimumab |
| N/A |
| Effects of Overdose of Adalimumab |
| N/A |
| Adalimumab Pharmacology |
| Adalimumab |
| About Adalimumab |
| Immunosuppressants, Human Monoclonal Antibody, Anti Rheumatic drug |
| Mechanism of Action of Adalimumab |
| Adalimumab is a recombinant DNA-derived human Ig G1 monoclonal antibody. It binds to human tumor necrosis factor alpha (TNF-?), thus interfering with cytokine-driven inflammatory processes |
| Pharmacokinets of Adalimumab |
| Absorption: Absorbed after SC administration Distribution: Widely distributed to the body Excretion: Excreted mainly through urine |
| Onset of Action for Adalimumab |
| N/A |
| Duration of Action for Adalimumab |
| N/A |
| Half Life of Adalimumab |
| 10 to 20 days |
| Side Effects of Adalimumab |
| 1.Hyperlipidaemia 2.Hypercholesterolaemia 3.Hypokalaemia 4.Hyperuricaemia 5.Headache 6.Drowsiness 7.Dizziness 8.Agitation 9.Tremor 10.Urinary frequency |
| Contra-indications of Adalimumab |
| Hypersensitivity |
| Special Precautions while taking Adalimumab |
| 1.Hepatic impairment 2.Renal impairment 3.Heart failure |
| Pregnancy Related Information |
| Contraindicated |
| Old Age Related Information |
| Use with caution |
| Breast Feeding Related Information |
| Contraindicated |
| Children Related Information |
| Use with caution |
| Indications for Adalimumab |
| 1.Rheumatoid arthritis 2.Ankylosing spondylitis 3.Crohn?s disease 4.Psoriatic arthritis 5.Ulcerative colitis |
| Interactions for Adalimumab |
| Avoid concomitant use of adalimumab with anakinra and live vaccines |
| Typical Dosage for Adalimumab |
| Dose for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic disease: 40 mg every other wk Dose for Crohn?s disease: 40 mg every other wk. For severe active disease: Initially, 160 mg given as 4 divided doses over 1-2 days, then 80 mg 2 wk after the initial dose. Maintenance: 40 mg every other wk; may increase to 40 mg wkly if needed |
| Schedule of Adalimumab |
| N/A |
| Storage Requirements for Adalimumab |
| Store between 2 to 8 degree celcius.Keep out of the reach of children |
| Effects of Missed Dosage of Adalimumab |
| N/A |
| Effects of Overdose of Adalimumab |
| N/A |